Home » Stocks » IMAB

I-Mab (IMAB)

Stock Price: $73.24 USD -4.73 (-6.07%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 5.64B
Revenue (ttm) 235.88M
Net Income (ttm) 72.01M
Shares Out 76.96M
EPS (ttm) 1.07
PE Ratio 68.64
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $73.24
Previous Close $77.97
Change ($) -4.73
Change (%) -6.07%
Day's Open 76.00
Day's Range 70.42 - 76.60
Day's Volume 883,400
52-Week Range 28.29 - 85.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile ABL503 currently in Phase 1 trial to evaluate the safety, tolerability...

2 weeks ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

2 weeks ago - PRNewsWire

First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors China sites to join the dose expansion part of the study to accelerate TJ- CD4B/...

3 weeks ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

3 weeks ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md. , June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializat...

3 weeks ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

4 weeks ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

1 month ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., June 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

1 month ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., June 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

1 month ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., May 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializatio...

1 month ago - PRNewsWire

I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG's (OTC: RHHBY) Tecentriq (atezolizumab) in patients with advanced cancer. An a...

2 months ago - Benzinga

Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerabi...

2 months ago - PRNewsWire

The phase 2 combination trial could potentially lead to a registrational study in China in 2022 Accelerated development plan for lemzoparlimab aiming for NDA approval in China for treatment of hematolog...

2 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., May 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

2 months ago - PRNewsWire

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

Other stocks mentioned: ALLK, HZNP, IBRX, MNMD, SAGE, SWTX
2 months ago - InvestorPlace

SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...

2 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...

2 months ago - PRNewsWire

I-Mab (NASDAQ: IMAB) has announced topline results from its Phase 2 study evaluating olamkicept (also known as TJ301) in patients with active ulcerative colitis (UC). The study met its primary endpoint ...

2 months ago - Benzinga

SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...

2 months ago - PRNewsWire

SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and co...

3 months ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and com...

3 months ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics...

3 months ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 29, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and com...

3 months ago - GlobeNewsWire

Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts

4 months ago - GlobeNewsWire

SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and com...

4 months ago - GlobeNewsWire

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst.  The I-Mab Analyst: Chad Messer initiated coverage of I-Mab ...

4 months ago - Benzinga

- New Initiative is part of I-Mab's long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology pla...

4 months ago - GlobeNewsWire

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or hi...

5 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the fir...

5 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

7 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

7 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

7 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

7 months ago - PRNewsWire

In a GuruFocus article on Nov. 17, I took a look at three of the nine public Chinese biotechnology companies that are projected to become major international competitors in the coming years, according t...

Other stocks mentioned: IVBXF
8 months ago - GuruFocus

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstratio...

Other stocks mentioned: BGNE, BNTX, CALT, MRK, PFE, TMO
8 months ago - Seeking Alpha

SHANGHAI and GAITHERSBURG, Md., Nov. 13, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

8 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

8 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

8 months ago - PRNewsWire

SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commerc...

8 months ago - PRNewsWire

SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

8 months ago - PRNewsWire

PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced t...

10 months ago - PRNewsWire

I-Mab (IMAB) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Companies in the news are: IMAB, LMPX, DPW, ANPC

Other stocks mentioned: ANPC, DPW
10 months ago - Zacks Investment Research

Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement.

Other stocks mentioned: ABBV
10 months ago - Seeking Alpha

I-Mab (IMAB) is seeing gains to IMAB stock on Friday after the biopharma company announced news of a deal with AbbVie (ABBV).

10 months ago - InvestorPlace

The deal could be the largest-ever out-licensing agreement by a Chinese biotech.

Other stocks mentioned: ABBV
10 months ago - The Motley Fool

Shares of I-Mab IMAB, +0.47% soared 17% in premarket trading Friday toward a record high, after the China-based biotechnology company announced a collaboration agreement with AbbVie Inc.

10 months ago - Market Watch

SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

10 months ago - PRNewsWire

About IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and O... [Read more...]

Industry
Biotechnology
IPO Date
Jan 17, 2020
Stock Exchange
NASDAQ
Ticker Symbol
IMAB
Full Company Profile

Financial Performance

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for I-Mab stock is "Strong Buy." The 12-month stock price forecast is 89.73, which is an increase of 22.52% from the latest price.

Price Target
$89.73
(22.52% upside)
Analyst Consensus: Strong Buy